erythropoietin


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

e·ryth·ro·poi·e·tin

 (ĭ-rĭth′rō-poi-ē′tĭn)
n.
1. A glycoprotein hormone that stimulates the production of red blood cells by stem cells in bone marrow. Produced mainly by the kidneys, it is released in response to decreased levels of oxygen in body tissue.
2. Epoetin alfa.

[erythropoiet(ic) + -in.]

erythropoietin

(ɪˌrɪθrəʊpɔɪˈiːtɪn)
n
(Biochemistry) a hormone, secreted by the kidney in response to low levels of oxygen in the tissues, that increases the rate of erythropoiesis. It has been used as a performance-enhancing drug for athletes and racehorses. Abbreviation: EPO

e•ryth•ro•poi•e•tin

(ɪˌrɪθ roʊˈpɔɪ ɪ tn, -pɔɪˈit n)

n.
a hormone that stimulates production of red blood cells and hemoglobin in the bone marrow.
[1945–50]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.erythropoietin - a glycoprotein secreted by the kidneys that stimulates the production of red blood cells
glycoprotein - a conjugated protein having a carbohydrate component
Translations
EpoetinErythropoetinErythropoietinHämatopoetin
eritropoietina

e·ryth·ro·poi·e·tin

[MIM*133170]
n. eritropoyetina, proteína no dializable que estimula la producción de eritrocitos.

erythropoietin

n eritropoyetina
References in periodicals archive ?
The global erythropoietin drugs market is projected to grow to USD 10.
Daprodustat will be evaluated in the two studies whether it is non-inferior or not to recombinant human erythropoietin on the endpoints considered as the primary analysis.
Following this, a number of biosimilar Erythropoietin alfa have been launched by major companies such as Biocon, Ranbaxy, Emcure Pharmaceuticals.
Technavio's analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.
Lawitz of Alamo Medical Research in San Antonio, adding that ribavirin dose reductions should be the initial strategy for managing anemia, followed, if necessary, by erythropoietin.
Erythropoietin is administered either by intravenous (IV) or subcutaneous (SC) route usually two to three times weekly in many dialysis centres (Churchill et al.
This article charts the history of anemia management in patients with ESRD, discusses the receptor science behind the discovery of erythropoietin and subsequent development of ESA therapy, and briefly reviews the mechanism of action and select attributes of ESAs.
A team of Swiss researchers found that when a hormone in the brain, erythropoietin (Epo), was elevated in mice, they were more motivated to exercise.
Erythropoietin is a treatment for anemia associated with chronic renal failure.
All investigations were done on day one before the start of therapy, and then treatment was initiated with recombinant human erythropoietin in a dose of 5000 IU subcutaneously and injection Iron Sucrose 200mg in 100cc NaCl intravenously on 3 alternate days.

Full browser ?